NASDAQ:OTLK

Outlook Therapeutics (OTLK) Stock Price, News & Analysis

$8.20
0.00 (0.00%)
(As of 05:45 PM ET)
Today's Range
$8.00
$8.66
50-Day Range
$5.73
$11.94
52-Week Range
$4.00
$40.60
Volume
339,873 shs
Average Volume
535,194 shs
Market Capitalization
$106.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.43

Outlook Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
466.8% Upside
$46.43 Price Target
Short Interest
Bearish
6.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.13mentions of Outlook Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$22,245 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.99) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.07 out of 5 stars

Medical Sector

348th out of 909 stocks

Biological Products, Except Diagnostic Industry

50th out of 156 stocks

OTLK stock logo

About Outlook Therapeutics Stock (NASDAQ:OTLK)

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OTLK Stock Price History

OTLK Stock News Headlines

The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
WGA Releases New Housing Finance Outlook
Outlook Therapeutics, Inc. (OTLK)
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
See More Headlines
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
4/24/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OTLK
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.43
High Stock Price Target
$100.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+466.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-58,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.11) per share

Miscellaneous

Free Float
12,323,000
Market Cap
$106.68 million
Optionable
Optionable
Beta
0.04
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives


OTLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Outlook Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OTLK shares.
View OTLK analyst ratings
or view top-rated stocks.

What is Outlook Therapeutics' stock price target for 2024?

8 analysts have issued 12-month price targets for Outlook Therapeutics' shares. Their OTLK share price targets range from $20.00 to $100.00. On average, they predict the company's stock price to reach $46.43 in the next year. This suggests a possible upside of 466.8% from the stock's current price.
View analysts price targets for OTLK
or view top-rated stocks among Wall Street analysts.

How have OTLK shares performed in 2024?

Outlook Therapeutics' stock was trading at $7.88 at the beginning of the year. Since then, OTLK stock has increased by 3.9% and is now trading at $8.19.
View the best growth stocks for 2024 here
.

Are investors shorting Outlook Therapeutics?

Outlook Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,330,000 shares, an increase of 69.4% from the March 15th total of 785,300 shares. Based on an average trading volume of 598,100 shares, the short-interest ratio is currently 2.2 days. Currently, 6.2% of the shares of the stock are sold short.
View Outlook Therapeutics' Short Interest
.

When is Outlook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our OTLK earnings forecast
.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.20.

When did Outlook Therapeutics' stock split?

Outlook Therapeutics's stock reverse split before market open on Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX).

How do I buy shares of Outlook Therapeutics?

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OTLK) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners